P97 inhibitors target the protein p97, a key player in cellular processes such as protein degradation and quality control. By inhibiting p97, these compounds disrupt these processes, making them a focus in cancer therapy. Blocking p97 can lead to the accumulation of misfolded proteins and ultimately cell death, making it a potential target in cancer treatment. Additionally, p97 inhibitors show promise in treating diseases like neurodegenerative disorders. However, they are still in preclinical and early clinical stages, with ongoing research to maximize their therapeutic potential.